Holen Sie sich die Stockscreener-App
7.10
2.61%
-0.19
Handel nachbörslich:
7.10
Schlusskurs vom Vortag:
$7.29
Offen:
$7.33
24-Stunden-Volumen:
1.72M
Relative Volume:
0.71
Marktkapitalisierung:
$918.99M
Einnahmen:
$8.40M
Nettoeinkommen (Verlust:
$-237.42M
KGV:
-3.6954
EPS:
-1.9213
Netto-Cashflow:
$-377.03M
1W Leistung:
-8.62%
1M Leistung:
-70.37%
6M Leistung:
-71.38%
1J Leistung:
+77.94%
1-Tages-Spanne:
$7.035
$7.38
1-Wochen-Bereich:
$7.035
$8.14
52-Wochen-Spanne:
$3.76
$31.35
Alumis Inc Stock (ALMS) Company Profile
Firmenname
Alumis Inc
Sektor
Branche
Telefon
650-231-6625
Adresse
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
7.10 | 918.99M | 8.40M | -237.42M | -377.03M | -1.9213 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-11 | Eingeleitet | Raymond James | Strong Buy |
| 2026-02-25 | Eingeleitet | Stifel | Buy |
| 2026-01-21 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-07-25 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-10 | Fortgesetzt | Guggenheim | Buy |
| 2025-01-30 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-31 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-10-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-07-23 | Eingeleitet | Guggenheim | Buy |
| 2024-07-23 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-23 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Alumis Inc Aktie (ALMS) Neueste Nachrichten
ALMS Stock Clocks Worst Day After 57% Drop — What Drove The Selloff? - Stocktwits
(ALMS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Cantor Fitzgerald reiterates Alumis stock rating on oral therapy outlook By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Alumis stock rating on oral therapy outlook - Investing.com
Why is Alumis stock rallying today? By Investing.com - Investing.com India
Alumis Insider Bought Shares Worth $10,726,255, According to a Recent SEC Filing - marketscreener.com
Alumis director Akkaraju buys $5.8m, sells $1m of ALMS shares - Investing.com India
Alumis at Cantor conference: psoriasis strength, lupus setback - investing.com
Alumis at Cantor conference: psoriasis strength, lupus setback By Investing.com - Investing.com Canada
Alumis (NASDAQ: ALMS) director buys 986K shares, agrees to give back trade profit - Stock Titan
ALMS Q2 2026 Earnings: Wider-than-Expected Loss Sends Shares Down 7.4%High Growth Earnings - careplusvn.com
Alumis (ALMS) Plans to Advance Envudeucitinib After LUMUS Missed in the Overall Population - Yahoo Finance
Alumis at Wells Fargo conference: lupus setback sharpens strategy By Investing.com - Investing.com Canada
Price-Driven Insight from (ALMS) for Rule-Based Strategy - Stock Traders Daily
Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven DiseasesSlideshow (NASDAQ:ALMS) 2026-09-04 - Seeking Alpha
Alumis to Participate in Upcoming September Investor Conferences - The Manila Times
Is Alumis (ALMS) Overvalued After Its 121% One Year Return? - Yahoo Finance
Alumis stock downgraded at Guggenheim (ALMS:NASDAQ) - Seeking Alpha
Why Alumis (ALMS) Is Down 56.2% After Mixed Phase 2b Lupus Data Spotlight Biomarker Strategy - finance.yahoo.com
Guggenheim Downgrades Alumis to Neutral From Buy - marketscreener.com
Alumis (ALMS) Looks Pricey After Its Lupus Trial Miss But Is 3x P B Fair? - Yahoo Finance
Alumis (ALMS) Lead Lupus Drug Missed Phase 2b Trial Endpoints - Yahoo Finance
Guggenheim downgrades Alumis stock rating after trial miss By Investing.com - Investing.com Canada
Guggenheim downgrades Alumis stock rating after trial miss - investing.com
Morgan Stanley cuts Alumis stock price target on lupus trial failure By Investing.com - Investing.com South Africa
Alumis (ALMS) Stock Slides As Momentum Traders Refocus On Fundamentals - timothysykes.com
Alumis' Share Price Fall After Envudeucitinib Trial Data Likely Overreaction, Oppenheimer Says - marketscreener.com
This OGE Energy Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday - Benzinga
Oppenheimer Adjusts Price Target on Alumis to $37 From $55, Maintains Outperform Rating - marketscreener.com
Morgan Stanley cuts Alumis stock price target on lupus trial failure - Investing.com India
Wells Fargo cuts Alumis stock price target on SLE trial results - Investing.com Australia
Wells Fargo cuts Alumis stock price target on SLE trial results By Investing.com - Investing.com South Africa
Alumis stock plunges 57% after lupus drug trial fails, but psoriasis drug progress continues. - Pluang
Alumis plunges 57% after trial failure; Enovis falls 16% on robotics acquisition news - Pluang
Alumis shares plunge after lupus trial failure, but drug potential remains uncertain - Pluang
Alumis: A Brutal Lupus Setback, But Psoriasis Still Supports Upside (NASDAQ:ALMS) - Seeking Alpha
Alumis Plunges 56% After Lupus Drug Fails Key Trial Goals - finance.biggo.com
Apple, Tesla, Nvidia, Medtronic, Alumis, Robinhood, Fervo, and More Stocks That Explain Today's Market -- Barrons.com - Moomoo
Alumis’ TYK2 drug fails in key lupus study - BioPharma Dive
Alumis Shares Plummet 59% After Lupus Study Failure Wipes Out $1.67 Billion - TechStock²
Alumis stock tumbles 55% after lupus drug trial misses goals By Investing.com - Investing.com Nigeria
Alumis stock tumbles 55% after lupus drug trial misses goals - Investing.com India
Alumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows Promise - TradingView
Why Is Alumis Stock Falling Tuesday? - Benzinga
Alumis Announces Topline Phase 2b Results for Envudeucitinib in Systemic Lupus Erythematosus - Kalkine Media
Alumis falls after TYK2 pill fails lupus study, but CEO sees 'clear path forward' - Endpoints News
Alumis falls after trial setback for lead drug (ALMS:NASDAQ) - Seeking Alpha
Why is Alumis stock collapsing today? By Investing.com - Investing.com Australia
Finanzdaten der Alumis Inc-Aktie (ALMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alumis Inc-Aktie (ALMS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| AKKARAJU SRINIVAS | Director |
Sep 04 '26 |
Buy |
11.17 |
440,140 |
4,917,684 |
4,711,801 |
| AKKARAJU SRINIVAS | Director |
Sep 08 '26 |
Sale |
10.55 |
96,131 |
1,014,028 |
2,025,493 |
| Schroer John R. | Chief Financial Officer |
Aug 03 '26 |
Sale |
26.37 |
3,282 |
86,546 |
24,718 |
| Pangali Sanam | Chief Legal Officer |
Aug 03 '26 |
Sale |
26.37 |
1,364 |
35,969 |
9,747 |
| Hardiman Roy C. | Chief Business & Strategy Ofcr |
Aug 03 '26 |
Sale |
26.37 |
2,692 |
70,988 |
207,746 |
| Goldstein David M | Chief Scientific Officer |
Aug 03 '26 |
Sale |
26.37 |
2,596 |
68,457 |
30,970 |
| Drappa Jorn | Chief Medical Officer |
Aug 03 '26 |
Sale |
26.37 |
2,447 |
64,527 |
56,892 |
| Bradley Mark Christopher | Chief Development Officer |
Aug 03 '26 |
Sale |
26.37 |
2,572 |
67,824 |
48,533 |
| Pangali Sanam | Chief Legal Officer |
Jul 06 '26 |
Option Exercise |
5.06 |
5,000 |
25,300 |
16,111 |
| Pangali Sanam | Chief Legal Officer |
Jul 06 '26 |
Sale |
28.00 |
5,000 |
140,000 |
11,111 |
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):